RASopathy syndromes: Understanding signaling pathway disorders leading to tumorigenesis.

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• RAS genes encode RAS proteins crucial for cell signaling.
• Mutations in RAS genes are implicated in over 30% of human cancers.
• RASopathies are genetic disorders linked to unregulated cell growth and tumorigenesis.

Purpose of the Study:

• To describe RAS genes, RASopathy syndromes, and their link to cancer.
• To explain how RAS gene mutations lead to cell signaling abnormalities and tumor formation.
• To discuss the therapeutic potential of MEK inhibitors in RASopathies and cancer.

Main Methods:

• Review of literature on RAS genes, RASopathies, and cancer genetics.
• Description of cell signaling pathways affected by RAS mutations.
• Case example of Neurofibromatosis type 1 (NF1) as a RASopathy.

Main Results:

• RAS gene mutations disrupt cell growth, differentiation, and apoptosis, promoting tumorigenesis.
• RASopathies predispose individuals to benign and malignant neoplasms.
• Abnormal cell signaling caused by RAS mutations can be targeted by MEK inhibitors.

Conclusions:

• RAS gene mutations are central to numerous cancers and RASopathy syndromes.
• Targeting RAS-driven cell signaling pathways, particularly with MEK inhibitors, offers therapeutic strategies for NF1 and other cancers.